NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has priced a public offering of 1.9 million securities units at $1.40 each for gross proceeds of roughly $2.7 million.

The units consist of one ordinary share and a warrant to purchase half an ordinary share. The warrants to purchase an aggregate of 974,987 ordinary shares have an exercise price of $1.50 per ordinary share. The warrants will become exercisable immediately upon issuance and expire in five years.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.